OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology
about
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the LiteratureThe role of botulinum toxin A in treating neurogenic bladderDelving into the complexity of hereditary spastic paraplegias: how unexpected phenotypes and inheritance modes are revolutionizing their nosologyChapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury.Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.Current and potential urological applications of botulinum toxin A.Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.Use of botulinum toxin for voiding dysfunction.Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity.Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis.Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in the mice.Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity.A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages.Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity.[What is new in symptomatic MS treatment: Part 3-bladder dysfunction].The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia.Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS
P2860
Q26749613-5E74EB7C-E891-453D-9083-C5BE3B4B38DFQ26767310-397C59D7-3D43-4C69-B85D-E1C89759EA07Q28081453-6EC2FBBE-FD77-4DD4-AD84-EABFC8088C10Q30837390-2895156D-3952-4F25-BD93-D67D260A2361Q35237161-F82FFB3B-5F3E-4CB0-9899-38C8C39E973FQ38233836-993C63A5-4DEB-449D-BA0C-71349C2B4B0FQ38508246-C08FC575-D42A-47EC-96AC-D22863C6FD6DQ38564108-792D84A4-AEA4-4479-8C28-70B1090DE2E1Q38675157-F2B5F4AD-3F35-49AF-BA64-26E13BFC4F9EQ38679555-57D97C10-0A9C-4269-A89D-675E006C8548Q38990447-88F913A1-1097-4D9F-A815-F2EC2FA54E53Q39210488-2C84CC0E-FE65-4835-B135-CA852AF366C5Q40949732-9B006618-E4C7-4605-ABC4-9CAEAB2FD747Q41110077-B589F295-9DDF-4448-BEF4-E8E6EFF78850Q45788137-F091BDCF-C42A-4C9A-B939-E3B5058A922AQ48065400-6B9C4D4F-74F5-4C29-A3D1-820DDB651806Q50100443-552A6CB3-0AFC-482C-9FAE-CC26081859F8Q53573594-C0A00D7E-ADAC-4061-82FB-C460E94B1EDAQ58780881-C42BB9DF-0BFC-48D8-B6FD-4D95120FE49D
P2860
OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
OnabotulinumtoxinA is effectiv ...... gic use or neurologic etiology
@en
OnabotulinumtoxinA is effectiv ...... ic use or neurologic etiology.
@nl
type
label
OnabotulinumtoxinA is effectiv ...... gic use or neurologic etiology
@en
OnabotulinumtoxinA is effectiv ...... ic use or neurologic etiology.
@nl
prefLabel
OnabotulinumtoxinA is effectiv ...... gic use or neurologic etiology
@en
OnabotulinumtoxinA is effectiv ...... ic use or neurologic etiology.
@nl
P2093
P2860
P1433
P1476
OnabotulinumtoxinA is effectiv ...... gic use or neurologic etiology
@en
P2093
Angelo Gousse
Brenda Jenkins
Catherine Thompson
Cornelia Haag-Molkenteller
David Ginsberg
Karl-Dietrich Sievert
Mitchell F Brin
Philip Aliotta
Sender Herschorn
Véronique Keppenne
P2860
P2888
P304
P356
10.1007/S12325-013-0054-Z
P407
P577
2013-09-27T00:00:00Z